TP53 and neoplasm: In LGIMAs, it seems clear that TP53 R273C may play a fundamental role in aggressiveness, and it has been postulated that this mutation could be an unfavorable prognostic biomarker for LGIMA patients and associated with higher tumor mutation burden values [9].